Bahareh Attaran1,2, Najmeh Salehi3, Bahareh Ghadiri1, Maryam Esmaeili1, Shadi Kalateh1, Mohammad Tashakoripour4, Mahmoud Eshagh Hosseini4, Marjan Mohammadi5. 1. HPGC Research Group, Department of Medical Biotechnology, Pasteur Institute of Iran, Tehran, Iran. 2. Department of Microbiology, Faculty of Biological Sciences, Alzahra University, Tehran, Iran. 3. Department of Bioinformatics, Institute of Biochemistry and Biophysics, University of Tehran, Tehran, Iran. 4. Gastroenterology Department, Amiralam Hospital, Tehran University of Medical Sciences, Tehran, Iran. 5. HPGC Research Group, Department of Medical Biotechnology, Pasteur Institute of Iran, Tehran, Iran. marjan.mohammadi@pasteur.ac.ir.
Abstract
BACKGROUND: Amoxicillin-resistant H. pylori strains are increasing worldwide. To explore the potential resistance mechanisms involved, the 3D structure modeling and access tunnel prediction for penicillin-binding proteins (PBP1A) was performed, based on the Streptococcus pneumoniae, PBP 3D structure. Molecular covalent docking was used to determine the interactions between amoxicillin (AMX) and PBP1A. RESULTS: The AMX-Ser368 covalent complex interacts with the binding site residues (Gly367, Ala369, ILE370, Lys371, Tyr416, Ser433, Thr541, Thr556, Gly557, Thr558, and Asn560) of PBP1A, non-covalently. Six tunnel-like structures, accessing the PBP1A binding site, were characterized, using the CAVER algorithm. Tunnel-1 was the ultimate access route, leading to the drug catalytic binding residue (Ser368). This tunnel comprises of eighteen amino acid residues, 8 of which are shared with the drug binding site. Subsequently, to screen the presence of PBP1A mutations, in the binding site and tunnel residues, in our clinical strains, in vitro assays were performed. H. pylori strains, isolated under gastroscopy, underwent AMX susceptibility testing by E-test. Of the 100 clinical strains tested, 4 were AMX-resistant. The transpeptidase domain of the pbp1a gene of these resistant, plus 10 randomly selected AMX-susceptible strains, were amplified and sequenced. Of the amino acids lining the tunnel-1 and binding site residues, three (Ser414Arg, Val469Met and Thr556Ser) substitutions, were detected in 2 of the 4 resistant and none of the sequenced susceptible strains, respectively. CONCLUSIONS: We hypothesize that mutations in amino acid residues lining the binding site and/or tunnel-1, resulting in conformational/spatial changes, may block drug binding to PBP1A and cause AMX resistance.
BACKGROUND:Amoxicillin-resistant H. pylori strains are increasing worldwide. To explore the potential resistance mechanisms involved, the 3D structure modeling and access tunnel prediction for penicillin-binding proteins (PBP1A) was performed, based on the Streptococcus pneumoniae, PBP 3D structure. Molecular covalent docking was used to determine the interactions between amoxicillin (AMX) and PBP1A. RESULTS: The AMX-Ser368 covalent complex interacts with the binding site residues (Gly367, Ala369, ILE370, Lys371, Tyr416, Ser433, Thr541, Thr556, Gly557, Thr558, and Asn560) of PBP1A, non-covalently. Six tunnel-like structures, accessing the PBP1A binding site, were characterized, using the CAVER algorithm. Tunnel-1 was the ultimate access route, leading to the drug catalytic binding residue (Ser368). This tunnel comprises of eighteen amino acid residues, 8 of which are shared with the drug binding site. Subsequently, to screen the presence of PBP1A mutations, in the binding site and tunnel residues, in our clinical strains, in vitro assays were performed. H. pylori strains, isolated under gastroscopy, underwent AMX susceptibility testing by E-test. Of the 100 clinical strains tested, 4 were AMX-resistant. The transpeptidase domain of the pbp1a gene of these resistant, plus 10 randomly selected AMX-susceptible strains, were amplified and sequenced. Of the amino acids lining the tunnel-1 and binding site residues, three (Ser414Arg, Val469Met and Thr556Ser) substitutions, were detected in 2 of the 4 resistant and none of the sequenced susceptible strains, respectively. CONCLUSIONS: We hypothesize that mutations in amino acid residues lining the binding site and/or tunnel-1, resulting in conformational/spatial changes, may block drug binding to PBP1A and cause AMX resistance.
Authors: Cai-Ping Gao; Di Zhang; Ting Zhang; Jin-Xia Wang; Sheng-Xi Han; David Y Graham; Hong Lu Journal: Helicobacter Date: 2020-04-20 Impact factor: 5.753
Authors: James K Y Hooi; Wan Ying Lai; Wee Khoon Ng; Michael M Y Suen; Fox E Underwood; Divine Tanyingoh; Peter Malfertheiner; David Y Graham; Vincent W S Wong; Justin C Y Wu; Francis K L Chan; Joseph J Y Sung; Gilaad G Kaplan; Siew C Ng Journal: Gastroenterology Date: 2017-04-27 Impact factor: 22.682
Authors: Amir Hossein Miri; Mojtaba Kamankesh; Antoni Llopis-Lorente; Chenguang Liu; Matthias G Wacker; Ismaeil Haririan; Hamid Asadzadeh Aghdaei; Michael R Hamblin; Abbas Yadegar; Mazda Rad-Malekshahi; Mohammad Reza Zali Journal: Front Pharmacol Date: 2022-06-27 Impact factor: 5.988